BioNTech asked U.S. regulators on Tuesday to approve an extra booster dose of their COVID-19 vaccine for seniors. The companies said Israeli data suggests that…
Posts published by “Daniel Scott”
Considered an asset in Health Courier, Daniel is revered for his degree in Biotechnology. Daniel is also renowned for his additional skills such as strategic planning, marketing skills, and organizational demeanor. Scott is highly revered for his exceptional dexterity in technical writing. Owing to his academic background in Biotechnology, Daniel has also actively participated in journalism workshops, besides undertaking a dedicated course in writing to further solidify his skill-set in objective journalism. One of the most talked-about roles of Daniel was his short stint in one of the leading news houses wherein he left an indelible mark in a new presentations. Gradually, Daniel diverted into editing, which he continued to do over the years in both print and electronic media.
Creyon Bio hopes to develop pharmaceuticals “on demand” for patient groups ranging from one person with a rare disease to “millions” of patients with common…
According to a senior official at Johnson & Johnson, the company is negotiating cooperation agreements with two Chinese companies as it seeks to capitalise on…
In lab studies, a California biotech company’s genetically engineered Poplar grew more than 1.5 times faster than unmodified Poplar, indicating that the company’s goal of…
Adagio Therapeutics, which is attempting to bring COVID-19 therapies to market after raising a large sum of money during the pandemic, will have to do…
Eli Lilly has rekindled his relationship with ImmunoGen. Lilly has negotiated a new arrangement, paying $13 million upfront and pledging up to $1.7 billion in…
Sana Biotechnology (SANA) is another high-valued cell treatment company that has yet to release any trial data. Despite this, it has a market capitalization of…
SPAC was the trendiest acronym on the market in late 2020 and the first half of 2021, but biotechs are less keen to seal mergers…
Unity Biotechnology, an anti-aging biotech, announced a half- Staff layoff and a reprioritization of its pipeline to focus on its ophthalmology assets a minute after…
In the near future, Sarepta Therapeutics will pay GenEdit up to $57 million for access to the Eli Lilly-backed biotech’s non-viral gene editing delivery platform.…